LIQUIDIA CORPORATION - COMMON STOCK

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

12 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Liquidia to Present at the Stifel 2024 Healthcare Conference

12 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent

07 Oct 2024 10:00:07 By Nasdaq GlobeNewswire

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

02 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

16 Sep 2024 09:41:30 By Nasdaq GlobeNewswire

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

11 Sep 2024 08:26:18 By Nasdaq GlobeNewswire

Liquidia to Present at Upcoming Investor Conferences

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

22 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

19 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions

16 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

18 Jun 2024 08:42:18 By Nasdaq GlobeNewswire

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference

29 May 2024 08:00:00 By Nasdaq GlobeNewswire